Intraventricular Medium B Treatment Benefits an Ischemic Stroke Rodent Model via Enhancement of Neurogenesis and Anti-apoptosis

Sci Rep. 2020 Apr 20;10(1):6596. doi: 10.1038/s41598-020-63598-0.

Abstract

Enhancement of endogenous neurogenesis after ischemic stroke may improve functional recovery. We previously demonstrated that medium B, which is a combination with epidermal growth factor (EGF) and fibronectin, can promote neural stem/progenitor cell (NSPC) proliferation and migration. Here, we showed that medium B promoted proliferation and migration of cultured NSPCs onto various 3-dimentional structures. When rat cortical neurons with oxygen glucose deprivation (OGD) were co-cultured with NSPCs, medium B treatment increased neuronal viability and reduced cell apoptosis. In a rat model with transient middle cerebral artery occlusion (MCAO), post-insult intraventricular medium B treatment enhanced proliferation, migration, and neuronal differentiation of NSPCs and diminished cell apoptosis in the infarct brain. In cultured post-OGD neuronal cells and the infarct brain from MCAO rats, medium B treatment increased protein levels of Bcl-xL, Bcl-2, phospho-Akt, phospho-GSK-3β, and β-catenin and decreased the cleaved caspase-3 level, which may be associated with the effects of anti-apoptosis. Notably, intraventricular medium B treatment increased neuronal density, improved motor function and reduced infarct size in MCAO rats. In summary, medium B treatment results in less neuronal death and better functional outcome in both cellular and rodent models of ischemic stroke, probably via promotion of neurogenesis and reduction of apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis* / drug effects
  • Brain Ischemia / complications
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / physiopathology
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Cerebral Ventricles / pathology*
  • Cerebral Ventricles / physiopathology
  • Disease Models, Animal
  • Epidermal Growth Factor / pharmacology
  • Epidermal Growth Factor / therapeutic use*
  • Fibronectins / pharmacology
  • Fibronectins / therapeutic use*
  • Glucose / deficiency
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / pathology
  • Infarction, Middle Cerebral Artery / physiopathology
  • Lateral Ventricles / pathology
  • Lateral Ventricles / physiopathology
  • Male
  • Neural Stem Cells / drug effects
  • Neural Stem Cells / ultrastructure
  • Neurogenesis* / drug effects
  • Neurons / drug effects
  • Neurons / pathology
  • Oxygen
  • Rats, Wistar
  • Recovery of Function / drug effects
  • Stroke / complications
  • Stroke / drug therapy*
  • Stroke / physiopathology

Substances

  • Fibronectins
  • Epidermal Growth Factor
  • Glucose
  • Oxygen